Lifecore Biomedical (NASDAQ:LFCR) Releases Earnings Results

Lifecore Biomedical (NASDAQ:LFCR) issued its quarterly earnings data on Wednesday. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.19), FiscalAI reports. The company had revenue of $23.19 million for the quarter, compared to analyst estimates of $25.96 million. Lifecore Biomedical had a negative return on equity of 1,211.09% and a negative net margin of 23.08%.

Here are the key takeaways from Lifecore Biomedical’s conference call:

• Reaffirmed 2026 guidance and mid?term targets — Lifecore reiterated 2026 revenue guidance of $120–125M and adjusted EBITDA of $20.5–25M, and reiterated a goal of 12% revenue CAGR and >25% EBITDA margin by end of 2029.
• Q1 results disappointed — revenue fell 34% year?over?year to $23.2M, gross profit declined and the company reported a $15M net loss with adjusted EBITDA of $1M, driven by front?loaded headwinds and timing shifts.
• Notable business development wins — signed three commercial site?transfer/CDMO agreements (including an aesthetics onshore transfer and two programs with a U.S. biopharma customer) and expanded a late?stage pipeline, with these transfers expected to be commercial by 2028 and represent mid?seven?figure opportunities each.
• Expense cuts and stronger liquidity — SG&A and R&D reduced by nearly $8M since late?2024, fifth consecutive quarter of positive operating cash flow, and ending Q1 liquidity of ~ $38M (~$21M cash + ~$17M revolver availability).
• Operational and quality progress — ERP implementation went smoothly in January, multiple customer inspections had positive outcomes, and the company is preparing to support a planned doubling of its largest customer’s commercial demand beginning in 2027.

Lifecore Biomedical Stock Performance

Shares of NASDAQ LFCR traded down $0.12 during midday trading on Thursday, reaching $4.84. 109,939 shares of the company’s stock were exchanged, compared to its average volume of 268,844. Lifecore Biomedical has a 52-week low of $3.63 and a 52-week high of $8.98. The stock has a market capitalization of $181.54 million, a PE ratio of -4.93 and a beta of 1.08. The business’s fifty day moving average price is $5.24 and its two-hundred day moving average price is $6.82.

Analysts Set New Price Targets

A number of research analysts have commented on LFCR shares. Barrington Research boosted their price objective on Lifecore Biomedical from $5.50 to $6.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 29th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Lifecore Biomedical in a research report on Tuesday, April 21st. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $6.00.

Institutional Trading of Lifecore Biomedical

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Millennium Management LLC increased its position in shares of Lifecore Biomedical by 86.2% during the fourth quarter. Millennium Management LLC now owns 251,705 shares of the company’s stock worth $2,059,000 after acquiring an additional 116,500 shares during the last quarter. AQR Capital Management LLC raised its stake in Lifecore Biomedical by 28.4% during the fourth quarter. AQR Capital Management LLC now owns 16,171 shares of the company’s stock valued at $132,000 after buying an additional 3,574 shares in the last quarter. Jump Financial LLC acquired a new stake in Lifecore Biomedical during the fourth quarter valued at approximately $123,000. Price T Rowe Associates Inc. MD raised its stake in Lifecore Biomedical by 20.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,646 shares of the company’s stock valued at $137,000 after buying an additional 2,826 shares in the last quarter. Finally, State of Wisconsin Investment Board raised its stake in Lifecore Biomedical by 138.2% during the fourth quarter. State of Wisconsin Investment Board now owns 37,825 shares of the company’s stock valued at $309,000 after buying an additional 21,946 shares in the last quarter. 83.36% of the stock is owned by hedge funds and other institutional investors.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.

The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care.